sing of aspirin in the prevention of preeclampsia
Not Applicable
- Conditions
- ??? ???????? ????-??? ???????? ????-??? ???????? ?? ????? ??? ???????Condition 1: Preeclampsia. Condition 2: preeclampsia.Gestational [pregnancy-induced] hypertension with significant proteinuriaO14.0,O14.
- Registration Number
- IRCT2013072914198N1
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Singleton pregnancies at 11-14 weeks and with riskfactors for preeclampsia such as;nulliparous women.
Exclusion criteria;Fetal chromosomal or structural abnormalities,allergy to acetylsalicylic tablets,medical conditions:renal,lupus and coronary artery heart disease,bleeding disorders.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diagnosis of preeclampsia. Timepoint: 2 month after onset-every 4 week-End of treatment. Method of measurement: Monitor of blood pressure and proteinuria.;Time of onset of preeclampsia. Timepoint: 2 month after onset-every 4 week-End of treatment. Method of measurement: LMP and ultrasound at time of booking.;Criteria of severity of preeclampsia. Timepoint: 2 month after onset-every 4 week-End of treatment. Method of measurement: Monitor for blood pressure and proteinuria and symptoms and signs.
- Secondary Outcome Measures
Name Time Method Maternal bleeding that need to transfusion. Timepoint: From delivery for 24 hours after. Method of measurement: Signe and symptoms-decreasing of Hb after delivery-nu.;Intrauterine growth restriction. Timepoint: 2??? ??? ?? ???? ??????-?? 4 ????-????? ??????. Method of measurement: When the fetal weight will below the 10th percentile for gestational in ultrasound and also when the neonatal birth weight will fill bellow the 10th percentile.;Preterm delivery. Timepoint: 2 month after onset-every 4 week-End of treatment. Method of measurement: LMP and ultrasound at time of booking.;Still birth. Timepoint: 2 month after onset-every 4 week-End of treatment. Method of measurement: With FHR monitoring and ultrasound.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie aspirin's efficacy in preventing preeclampsia via uterine Doppler abnormalities?
How does low-dose aspirin compare to standard-of-care antihypertensives in high-risk pregnancies with abnormal uterine Doppler?
Which biomarkers correlate with aspirin response in preeclampsia prevention for Doppler-identified high-risk pregnancies?
What adverse events are associated with low-dose aspirin use in gestational hypertension with proteinuria (O14.0, O14) populations?
Are there combination therapies or alternative antiplatelet agents showing superior preeclampsia prevention in Doppler-abnormal pregnancies?